Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment
Endometrial cancer (EC), while generally curable in early stages, poses significant challenges when it recurs or advances. Recent advancements in immunotherapy, specifically immune checkpoint inhibitors, have provided a promising therapeutic option for such cases, especially with FDA-approved drugs...
| Autores: | , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Recursos: | Universitat de Lleida (UdL) |
| Repositorio: | Repositori Obert UdL |
| OAI Identifier: | oai:repositori.udl.cat:10459.1/467181 |
| Acesso em linha: | https://doi.org/10.3390/cancers16233918 https://hdl.handle.net/10459.1/467181 |
| Access Level: | acceso abierto |
| Palavra-chave: | Endometrial cancer Immunotherapy Mismatch repair Tumor mutational burden Tumor microenvironment Immune checkpoint blockade Cell-based therapies |
| Resumo: | Endometrial cancer (EC), while generally curable in early stages, poses significant challenges when it recurs or advances. Recent advancements in immunotherapy, specifically immune checkpoint inhibitors, have provided a promising therapeutic option for such cases, especially with FDA-approved drugs like pembrolizumab, durvalumab, and dostarlimab. The molecular classification of EC, particularly mismatch repair deficiency, has proven essential in identifying tumors that are likely to respond to immune checkpoint inhibitors, owing to their increased tumor mutational burden and higher PD-L1 expression. However, mismatch repair (MMR) status alone is insufficient to predict immune responses as treatment outcomes are also substantially influenced by tumor microenvironment composition, immune infiltration, and inter-individual variability. Emerging cell therapies like Chimeric Antigen Receptor (CAR) T cells and tumor-infiltrating lymphocytes offer hope for addressing non-immunogenic tumors, overcoming immune evasion mechanisms that limit natural immune responses. |
|---|